BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015;8:298-312. [PMID: 26327920 DOI: 10.1177/1756283X15587481] [Cited by in Crossref: 73] [Cited by in F6Publishing: 23] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhang G, Patel K, Moghe A, Reid A, Serper M, Calgaro L, Gibson S, Zickmund S, Shaikh O, Rogal S. Provider Perceptions of Hepatitis C Treatment Adherence and Initiation. Dig Dis Sci 2020;65:1324-33. [PMID: 31642008 DOI: 10.1007/s10620-019-05877-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Yuan Q, Cui H, Leya GA, Hong S, Roth EM, Sise ME, Bethea ED, Yeh H, Williams WW, Elias N. Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus. Transpl Int 2021;34:2562-9. [PMID: 34726801 DOI: 10.1111/tri.14152] [Reference Citation Analysis]
3 Ravinetto R, De Weggheleire A, Dorlo TP, Francque S, Sokkab A, Pouget C, Meessen B, Tabernero P, Newton PN, Lynen L. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Trop Med Int Health 2016;21:1490-5. [PMID: 27671365 DOI: 10.1111/tmi.12784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One 2017;12:e0172159. [PMID: 28245248 DOI: 10.1371/journal.pone.0172159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
5 Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, Mengoni F, Mastroianni CM, Vullo V, Lichtner M. Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One 2017;12:e0179400. [PMID: 28636655 DOI: 10.1371/journal.pone.0179400] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
6 Kostadinova L, Shive CL, Zebrowski E, Fuller B, Rife K, Hirsch A, Compan A, Moreland A, Falck-Ytter Y, Popkin DL, Anthony DD. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. Pathog Immun 2018;3:149-63. [PMID: 30370392 DOI: 10.20411/pai.v3i1.242] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
7 Hegade VS, Speight RA, Etherington RE, Jones DE. Novel bile acid therapeutics for the treatment of chronic liver diseases. Therap Adv Gastroenterol 2016;9:376-91. [PMID: 27134666 DOI: 10.1177/1756283X16630712] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
8 Huang YT, Hsieh YY, Chen WM, Tung SY, Wei KL, Shen CH, Chang KC, Lu CK, Yen CW, Lu SN, Hung CH, Chang TS. Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol 2021;21:259. [PMID: 34118889 DOI: 10.1186/s12876-021-01837-y] [Reference Citation Analysis]
9 Vijgen L, Thys K, Vandebosch A, Van Remoortere P, Verloes R, De Meyer S. Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845. Virol J 2017;14:101. [PMID: 28569206 DOI: 10.1186/s12985-017-0760-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Hegazy MT, Allam WR, Hussein MA, Zoheir N, Quartuccio L, El-Khamisy SF, Ragab G; Mediterranean Consortium for the study of Cryoglobulinemic Vasculitis. Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs. EBioMedicine 2018;35:106-13. [PMID: 30139628 DOI: 10.1016/j.ebiom.2018.08.007] [Reference Citation Analysis]
11 Youssef NF, El Kassas M, Farag A, Shepherd A. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt. BMC Gastroenterol 2017;17:18. [PMID: 28109264 DOI: 10.1186/s12876-017-0581-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
12 Aby E, Jimenez MA, Grotts JF, Agopian V, French SW, Busuttil RW, Saab S. Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. J Clin Transl Hepatol 2017;5:197-202. [PMID: 28936400 DOI: 10.14218/JCTH.2016.00073] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Johnson L, Lewer D, Aldridge RW, Hayward AC, Story A. Protocol for a systematic review of treatment adherence for HIV, hepatitis C and tuberculosis among homeless populations. Syst Rev 2020;9:211. [PMID: 32921306 DOI: 10.1186/s13643-020-01470-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Grosgebauer K, Bartholomew TS, Huynh K, Cos T. Impact of Behavioral Health Consultation on Hepatitis C Treatment Outcomes at a Federally Qualified Health Center; Philadelphia, PA. J Prim Prev 2021;42:203-15. [PMID: 33733379 DOI: 10.1007/s10935-021-00627-2] [Reference Citation Analysis]
15 Danilescu CM, Sandulescu DL, Pirlog MC, Streba CT, Rogoveanu I. Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy. Diagnostics (Basel) 2021;11:2237. [PMID: 34943472 DOI: 10.3390/diagnostics11122237] [Reference Citation Analysis]
16 Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0141715. [PMID: 26558905 DOI: 10.1371/journal.pone.0141715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
17 Yang L, Jiang C, Hu S, Diao Q, Li J, Si W, Chen M, Zhao RY. Evolving Diversity of Hepatitis C Viruses in Yunnan Honghe, China. Int J Mol Sci 2016;17:403. [PMID: 26999127 DOI: 10.3390/ijms17030403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS 2016;11:527-36. [PMID: 27367780 DOI: 10.1097/COH.0000000000000305] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 12.2] [Reference Citation Analysis]
19 Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, Panese S, Monarca R, Prestileo T, Barbarini G, Babudieri S; SIMSPe Group. Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel. Infection. 2017;45:131-138. [PMID: 28025726 DOI: 10.1007/s15010-016-0973-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
20 Abutaleb A, Kottilil S. Vedroprevir in the management of hepatitis C virus infection. Expert Opin Investig Drugs 2017;26:1399-402. [PMID: 29053394 DOI: 10.1080/13543784.2017.1395412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Qian XJ, Zhang XL, Zhao P, Jin YS, Chen HS, Xu QQ, Ren H, Zhu SY, Tang HL, Zhu YZ. A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes. Sci Rep. 2016;6:27268. [PMID: 27252043 DOI: 10.1038/srep27268] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
22 He X, Hopkins L, Everett G, Carter WM, SchroppDyce C, Abusaada K, Hsu V. Safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in hepatitis C virus/human immunodeficiency virus co-infected patients. World J Hepatol 2017; 9(30): 1190-1196 [PMID: 29109851 DOI: 10.4254/wjh.v9.i30.1190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Khuhro Q, Shaikh H, Washdev, Hashmi S. Depression trends in Hepatitis-C PCR positive and PCR negative patients. Pak J Med Sci 2022;38:162-6. [PMID: 35035419 DOI: 10.12669/pjms.38.1.4788] [Reference Citation Analysis]
24 Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S. Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. Health Qual Life Outcomes 2017;15:25. [PMID: 28143559 DOI: 10.1186/s12955-017-0598-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
25 Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
26 Xiao W, Lu MH, Rong PF, Zhang HY, Gong J, Peng YQ, Gong HY, Liu ZG. 11β‑hydroxysteroid dehydrogenase‑1 is associated with the activation of hepatic stellate cells in the development of hepatic fibrosis. Mol Med Rep 2020;22:3191-200. [PMID: 32945429 DOI: 10.3892/mmr.2020.11423] [Reference Citation Analysis]